Effects of an angiotensin-converting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention patients: RAICES Study

AIMSTo evaluate the hypothesis that angiotensin-converting enzyme inhibitor therapy with ramipril reduces baseline levels of C-reactive protein in patients at high cardiovascular risk. METHODSSecondary prevention patients were screened for eligibility and treated with ramipril for 6 month. Baseline...

Full description

Saved in:

Bibliographic Details
Published in:	Coronary artery disease Vol. 16; no. 7; pp. 423 - 429
Main Authors:	Lopez Santi, Ricardo G, Valeff, Eduardo C, Duymovich, Claudio R, Mazziotta, Daniel, Mijailovsky, Norma E, Filippa, Gerardo C, Maltez, Raúl, Hernandez, Violeta A, Monroy, Alejandro Gomez, Borzi, Jorge G, Acheme, Rosana A, Etchegoyen, María C
Format:	Journal Article
Language:	English
Published:	England Lippincott Williams & Wilkins, Inc 01-11-2005
Subjects:	Aged Angiotensin-Converting Enzyme Inhibitors - pharmacology C-Reactive Protein - analysis C-Reactive Protein - drug effects Cardiovascular Diseases - prevention & control Drug Therapy, Combination Female Humans Inflammation - prevention & control Male Middle Aged Ramipril - pharmacology Risk Factors Secondary Prevention
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	AIMSTo evaluate the hypothesis that angiotensin-converting enzyme inhibitor therapy with ramipril reduces baseline levels of C-reactive protein in patients at high cardiovascular risk. METHODSSecondary prevention patients were screened for eligibility and treated with ramipril for 6 month. Baseline and 6-month highly sensitive C-reactive protein levels were determined. RESULTSA total of 77 patients were analyzed. The median highly sensitive C-reactive protein concentration at baseline was 2.17 mg/l (interquartile interval 0.97–4.54); whereas in post-treatment, the median was 1.70 mg/l (interquartile interval 0.88–3.41), P=0.0009. Patients were stratified according to risk level determined by baseline highly sensitive C-reactive protein levelslow-risk (<1 mg/l), intermediate risk (1–3 mg/l) and high risk (>3 mg/l) The reduction in highly sensitive C-reactive protein occurred at the expense of the high-risk group (baseline 5.02 mg/l, post-treatment 3.3 mg/l, P<0.0001), with no differences in the other groups. In multiple regression analysis, the reduction observed in the high-risk group could not be explained by baseline treatment or change in any of the variables analyzed. CONCLUSIONHighly sensitive C-reactive protein levels were reduced after a 6-month ramipril therapy in secondary prevention patients, suggesting an anti-inflammatory effect of angiotensin-converting enzyme inhibitors. Future investigations will be done to confirm these results, and to investigate how angiotensin-converting enzyme inhibitor treatment elicits anti-inflammatory effects.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	0954-6928 1473-5830
DOI:	10.1097/00019501-200510000-00002